JP2019532031A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532031A5 JP2019532031A5 JP2019511658A JP2019511658A JP2019532031A5 JP 2019532031 A5 JP2019532031 A5 JP 2019532031A5 JP 2019511658 A JP2019511658 A JP 2019511658A JP 2019511658 A JP2019511658 A JP 2019511658A JP 2019532031 A5 JP2019532031 A5 JP 2019532031A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylenyl
- hydrogen
- heterocyclyl
- carbocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 229910052739 hydrogen Inorganic materials 0.000 claims 30
- 239000001257 hydrogen Substances 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 125000004452 carbocyclyl group Chemical group 0.000 claims 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 17
- 125000005843 halogen group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 125000005466 alkylenyl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 229960002436 cladribine Drugs 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- VZKYFJQZMLDYED-UHFFFAOYSA-N CC(C)NC(CN1CCCC1)=O Chemical compound CC(C)NC(CN1CCCC1)=O VZKYFJQZMLDYED-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381383P | 2016-08-30 | 2016-08-30 | |
| US62/381,383 | 2016-08-30 | ||
| US201662437533P | 2016-12-21 | 2016-12-21 | |
| US62/437,533 | 2016-12-21 | ||
| PCT/US2017/049462 WO2018045084A1 (en) | 2016-08-30 | 2017-08-30 | Tetracycline compounds and methods of treatment |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2019532031A JP2019532031A (ja) | 2019-11-07 |
| JP2019532031A5 true JP2019532031A5 (OSRAM) | 2020-10-08 |
| JP7184756B2 JP7184756B2 (ja) | 2022-12-06 |
| JP7184756B6 JP7184756B6 (ja) | 2022-12-20 |
Family
ID=59982459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511658A Active JP7184756B6 (ja) | 2016-08-30 | 2017-08-30 | テトラサイクリン化合物および処置方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230031954A1 (OSRAM) |
| EP (1) | EP3506908A1 (OSRAM) |
| JP (1) | JP7184756B6 (OSRAM) |
| KR (1) | KR102558540B1 (OSRAM) |
| CN (1) | CN110167560B (OSRAM) |
| AU (1) | AU2017319513B2 (OSRAM) |
| CA (1) | CA3034891A1 (OSRAM) |
| CL (1) | CL2019000542A1 (OSRAM) |
| CO (1) | CO2019002975A2 (OSRAM) |
| IL (1) | IL264878B (OSRAM) |
| MA (1) | MA46102A (OSRAM) |
| MX (1) | MX2019002453A (OSRAM) |
| MY (1) | MY204572A (OSRAM) |
| SG (2) | SG11201901390TA (OSRAM) |
| WO (1) | WO2018045084A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108329312B (zh) | 2012-08-31 | 2021-12-31 | 四相制药公司 | 四环素化合物 |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| DK3377488T3 (da) | 2015-11-19 | 2022-10-03 | Incyte Corp | Heterocykliske forbindelser som immunomodulatorer |
| MY199705A (en) | 2015-12-22 | 2023-11-20 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| HUE066360T2 (hu) | 2016-10-19 | 2024-07-28 | Tetraphase Pharmaceuticals Inc | Eravaciklin kristályformái |
| WO2018119266A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| US20180179202A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| FI3774791T3 (fi) | 2018-03-30 | 2023-03-21 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
| BR112020022936A2 (pt) | 2018-05-11 | 2021-02-02 | Incyte Corporation | derivados de tetra-hidro-imidazo[4,5-c]piridina como imunomoduladores de pd-l1 |
| WO2021022258A1 (en) * | 2019-08-01 | 2021-02-04 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds for the treatment of hematological cancers |
| US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
| MX2022003578A (es) | 2019-09-30 | 2022-05-30 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores. |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| AU2021289665A1 (en) | 2020-06-10 | 2022-12-15 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| MX2023005362A (es) | 2020-11-06 | 2023-06-22 | Incyte Corp | Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo. |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| CA3224494A1 (en) | 2021-07-09 | 2023-01-12 | Koen Vandyck | Anti-viral compounds |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1077598A (en) * | 1965-05-12 | 1967-08-02 | Pfizer & Co C | Preparation of n-demethyl tetracyclines |
| WO2005082860A1 (en) * | 2004-02-27 | 2005-09-09 | National Research Council Of Canada | Tetracyclines and their use as calpain inhibitors |
| CA2564325A1 (en) * | 2004-04-30 | 2005-11-24 | Bayer Pharmaceuticals Corporation | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| HRP20130928T1 (hr) * | 2008-08-08 | 2013-11-22 | Tetraphase Pharmaceuticals, Inc. | C7-fluor supstituirani spojevi tetraciklina |
| US9315451B2 (en) * | 2009-05-08 | 2016-04-19 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
| WO2010129055A1 (en) | 2009-05-08 | 2010-11-11 | Tetraphase Pharmaceuticals, Inc. | 8-aza tetracycline compounds |
| DK2470500T3 (en) * | 2009-08-28 | 2018-01-08 | Tetraphase Pharmaceuticals Inc | tetracycline |
| EP2544692A4 (en) * | 2010-03-10 | 2013-08-07 | Univ Health Network | USE OF TIGECYCLIN FOR THE TREATMENT OF CANCER |
| JP5820462B2 (ja) * | 2010-03-31 | 2015-11-24 | テトラフェース ファーマシューティカルズ，インコーポレイテッド | 多環式テトラサイクリン化合物 |
| NZ603792A (en) | 2010-05-21 | 2015-07-31 | Abbvie Inc | Modulators of 5-ht receptors and methods of use thereof |
| TW201245116A (en) * | 2010-08-12 | 2012-11-16 | Tetraphase Pharmaceuticals Inc | Tetracycline analogs |
| SE536617C2 (sv) | 2012-06-28 | 2014-04-01 | Cargine Engineering Ab | Metod och positioneringssensorsammansättning för fastställning av en inbördes position mellan ett första objekt och ettandra objekt |
| CN108329312B (zh) * | 2012-08-31 | 2021-12-31 | 四相制药公司 | 四环素化合物 |
-
2017
- 2017-08-30 CN CN201780064847.8A patent/CN110167560B/zh active Active
- 2017-08-30 US US16/328,559 patent/US20230031954A1/en not_active Abandoned
- 2017-08-30 MA MA046102A patent/MA46102A/fr unknown
- 2017-08-30 CA CA3034891A patent/CA3034891A1/en active Pending
- 2017-08-30 WO PCT/US2017/049462 patent/WO2018045084A1/en not_active Ceased
- 2017-08-30 SG SG11201901390TA patent/SG11201901390TA/en unknown
- 2017-08-30 JP JP2019511658A patent/JP7184756B6/ja active Active
- 2017-08-30 SG SG10202101986UA patent/SG10202101986UA/en unknown
- 2017-08-30 KR KR1020197008575A patent/KR102558540B1/ko active Active
- 2017-08-30 MY MYPI2019001102A patent/MY204572A/en unknown
- 2017-08-30 MX MX2019002453A patent/MX2019002453A/es unknown
- 2017-08-30 IL IL264878A patent/IL264878B/en unknown
- 2017-08-30 AU AU2017319513A patent/AU2017319513B2/en active Active
- 2017-08-30 EP EP17777422.1A patent/EP3506908A1/en active Pending
-
2019
- 2019-02-28 CL CL2019000542A patent/CL2019000542A1/es unknown
- 2019-03-27 CO CONC2019/0002975A patent/CO2019002975A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532031A5 (OSRAM) | ||
| JP2018528946A5 (OSRAM) | ||
| JP2016506962A5 (OSRAM) | ||
| JP2014511892A5 (OSRAM) | ||
| JP2015514806A5 (OSRAM) | ||
| JP2013520473A5 (OSRAM) | ||
| GB201201744D0 (en) | Novel compounds | |
| HRP20161478T1 (hr) | Inhibitori protein kinaze (varijante), njihova upotreba za liječenje neuroloških bolesti, kao i farmaceutski pripravak koji se na njima temelji | |
| JP2017537949A5 (OSRAM) | ||
| JP2018535963A5 (OSRAM) | ||
| JP2016530259A5 (OSRAM) | ||
| JP2018507877A5 (OSRAM) | ||
| JP2014505660A5 (OSRAM) | ||
| TW200643015A (en) | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives | |
| JP2018516917A5 (OSRAM) | ||
| HRP20240375T1 (hr) | Derivati aminopirimidina kao inhibitori ctps1 | |
| JP2014511891A5 (OSRAM) | ||
| AR037329A1 (es) | Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos | |
| AR040500A1 (es) | Inhibidores de cinasas | |
| JP2018534288A5 (OSRAM) | ||
| JP2019504067A5 (OSRAM) | ||
| JP2019505529A5 (OSRAM) | ||
| AR097199A1 (es) | Inhibidores de rorc2 y sus métodos de uso | |
| JP2020520957A5 (OSRAM) | ||
| RU2018142988A (ru) | Производные пиридиндикарбоксамида в качестве ингибиторов бромодомена |